Astellas Pharma Inc.
アステラス製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4503
FY2025 (Mar 2026) · IFRS · consolidated Source: filing S100YBPK
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 80.9% |
|---|---|
| Operating margin | 17.9% |
| Net margin | 13.6% |
| Return on equity | 17.4%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 8.4% |
| Revenue growth (YoY) | 11.9% |
| EPS (basic) | ¥162.77 |
| EPS growth (YoY) | 474.1% |
| Current ratio | 1.17x |
| Equity ratio | 51.3% |
| Book value / share | ¥1,020.96 |
| Free cash flow | ¥475.5B |